Reuters logo
BRIEF-Merck announces findings from phase 3 study of KEYTRUDA
September 11, 2017 / 1:20 PM / 12 days ago

BRIEF-Merck announces findings from phase 3 study of KEYTRUDA

Sept 11 (Reuters) - Merck & Co Inc

* Merck announces findings from phase 3 study of KEYTRUDA (pembrolizumab), compared to standard of care, in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma

* Merck - ‍findings include updated survival data showing a 19 percent reduction in risk of death over standard treatment in intent-to-treat population​

* Merck & co-deaths due to treatment-related adverse events occurred in 4 patients (1.6%) in KEYTRUDA arm & 2 patients (0.9%) in standard treatment arm

* Merck & Co Inc - ‍safety profile of KEYTRUDA was consistent with that observed in previously reported studies​

* Merck & Co Inc - ‍primary efficacy analysis of study “did not show a statistically significant improvement in overall survival”​

* Merck - ‍treatment-related adverse events (TRAES) of any grade occurred in 63.0% patients in KEYTRUDA arm and 83.8% patients in standard treatment arm​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below